SuperworthAdicet Bio EPS ACET
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$11.44
- Latest quarter, Q2 FY26
- −$1.99
- Fiscal year 2025
- −$18.01
Adicet Bio's earnings per share was −$11.44 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.99.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$18.01 | n/a |
| FY2024 | −$21.44 | n/a |
| FY2023 | −$52.96 | n/a |
| FY2022 | −$27.04 | n/a |
| FY2021 | −$33.12 | n/a |
| FY2020 | −$148.00 | n/a |
| FY2019 | −$298.08 | n/a |
| FY2018 | −$162.40 | n/a |
| FY2017 | −$896.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.99 | n/a | −$11.44 | |
| Q1 FY26 | −$1.88 | n/a | −$14.93 | |
| Q4 FY25 | −$2.93 | n/a | −$18.01 | |
| Q3 FY25 | −$4.64 | n/a | −$20.20 | |
| Q2 FY25 | −$5.48 | n/a | −$21.00 | |
| Q1 FY25 | −$4.96 | n/a | −$20.80 | |
| Q4 FY24 | −$5.12 | n/a | −$21.44 | |
| Q3 FY24 | −$5.44 | n/a | −$27.20 | |
| Q2 FY24 | −$5.28 | n/a | −$40.32 | |
| Q1 FY24 | −$5.60 | n/a | −$47.04 | |
| Q4 FY23 | −$10.88 | n/a | −$52.96 | |
| Q3 FY23 | −$18.56 | n/a | −$53.28 |
Against its peers
Companies in Drug Manufacturers - General nearest Adicet Bio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ACETAdicet Bio | −$11.44 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Adicet Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.